Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

Bausch + Lomb SeeLyra CE Mark Approval

Analysis based on 6 articles · First reported Sep 11, 2026 · Last updated Sep 11, 2026

Sentiment
5
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The CE Mark approval strengthens Bausch Health — Bausch & Lomb's competitive position in the European ophthalmic surgical device market and could support incremental revenue growth from premium cataract and LASIK procedures. The impact is likely modest and company-specific, with limited broader market implications.

medical devices ophthalmology healthcare

Bausch Health — Bausch & Lomb Corporation announced that the European Union granted CE Mark approval for SeeLyra, its next-generation femtosecond laser platform. SeeLyra is designed to provide surgeons with enhanced precision and control in laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic surgeries. The compact system integrates real-time swept source OCT imaging, enabling accurate depth visualization and precise positioning of laser cuts, and its mobility and versatile configurations are tailored for modern, space-constrained operating rooms. Building on more than 15 years of experience in femtocataract laser technology, SeeLyra retains key features from Bausch Health — Bausch & Lomb's earlier VICTUS platform while introducing new capabilities. SeeLyra will be available in Europe on a limited basis in the coming months, with broader availability expected in 2027. Bausch Health — Bausch & Lomb is also seeking regulatory approvals for SeeLyra in markets around the world, including the United States, with indications and approvals varying by country. The approval expands the company's surgical technology offerings in Europe and supports its premium cataract and refractive surgery franchise.

90 European Union granted CE Mark approval Bausch Health — Bausch & Lomb
85 Bausch Health — Bausch & Lomb announced CE Mark approval
50 Bausch Health — Bausch & Lomb seeking regulatory approvals United States
subs
Bausch Health — Bausch & Lomb received CE Mark approval for its next-generation SeeLyra femtosecond laser, expanding its European surgical device portfolio. The approval is a positive but incremental development for the company's premium cataract and refractive surgery business.
Importance 100.0 Sentiment 15.0
alliance
The European Union granted CE Mark approval for SeeLyra, enabling Bausch Health — Bausch & Lomb to market the device in Europe. The action reflects the EU's regulatory role in medical device approvals.
Importance 40.0 Sentiment 0.0
cnt
Bausch Health — Bausch & Lomb is seeking regulatory approval for SeeLyra in the United States, making the US a potential future market for the device. No US regulatory decision has been announced.
Importance 15.0 Sentiment 0.0
oth
A physician affiliated with the University of Zaragoza provided a supportive comment on SeeLyra's clinical utility. The institution has no material financial role in the event.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.